Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Pyridoclax is an inhibitor of potential Mcl-1.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
2 mg | 5 days | $ 82.00 |
Description | Pyridoclax is an inhibitor of potential Mcl-1. |
In vitro | Pyridoclax directly binds to Mcl-1. Pyridoclax induces apoptosis in combination with Bcl-xL-targeting siRNA or with ABT-737 in ovarian, lung, and mesothelioma cancer cells. Pyridoclax causes apoptosis in ovarian, and also in lung, and mesothelioma cancer cells when it is administrated in combination with Bcl-xL-targeting siRNA or Bcl-xL targeting molecules such as ABT-737 or its orally available derivative ABT-263. Pyridoclax sensitizes ovarian carcinoma cells to Bcl-xL-targeting strategies [1][2]. |
Synonyms | MR-29072 |
Molecular Weight | 426.51 |
Formula | C29H22N4 |
CAS No. | 1651890-44-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 20 mg/mL (46.89 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Pyridoclax 1651890-44-6 Apoptosis BCL MR29072 MR-29072 MR 29072 inhibitor inhibit